China Tracker - Details for 3SBio Inc. (SSRX)

 3SBio Inc.
 Business Outlook

3SBio reiterates 2011 net revenues guidance of $76 million - $82 million.

(Source: PR Newswire, 2011-08-15)

We remain on track to achieve our key objectives for 2011 and reiterate our full year guidance of 20-30% top line growth. We launched our marketing and educational campaign in key cities for the recently approved TPIAO for ITP indication. We also submitted an application to the SFDA to conduct clinical trials for voclosporin. We are now working with a partner to obtain regulatory approval for EPIAO in Malaysia. If successful, it will be one of the first biosimilar EPO products to be approved in Malaysia, one of the 39 members of the Pharmaceutical Inspection Cooperation Scheme ("PIC/S"). Our export sales efforts continue to focus on forming strong marketing partnerships and seeking regulatory approval in those developed markets where our new state-of-the-art production facility, low production costs and recognized product quality provide us with a commercial edge over our international competitors.

(Source: PR Newswire, 2011-05-11)

Based on current market and operating conditions and the following goals, the Company's total net revenues target for the full year 2011 is between US$76 million to US$82 million, an estimated year-over-year increase of approximately 20% to 30%. Other operating objectives include: Secure new product approval for 36,000 IU dosage formulation of EPIAO and Nuleusin. Initiate Phase I trial of NuPiao, our next-generation EPO product. Initiate a registration trial of Feraheme, an IV iron supplement. Continue to explore global biosimilar opportunities and initiate the approval process in selected markets. Work with Isotechnika on initiating a global Phase III multi-center trial of voclosporin for the prevention of kidney transplant rejection. Prepare application to conduct clinical trials in China for pegsiticase (Uricase-PEG 20), a treatment for refractory gout, and identify potential partners for development outside China. Strengthen existing strategic partnerships while continuing to seek opportunities that leverage our balance sheet, strong nephrology and oncology franchises and recent additions to our product pipeline.

(Source: PR Newswire, 2011-03-16)

Based on current market conditions and visibility provided during the third quarter, the Company reiterates its total net revenue target for the full year of 2010 of between US$56 million to US$60 million, resulting in a year-over-year increase of approximately 21% to 29%.

(Source: PR Newswire, 2010-11-15)

We have raised our 2010 full year net revenues guidance from US$56-58 million to US$56-60 million, due to the strong first quarter sales performance.

(Source: PR Newswire, 2010-07-04)
SSRX
Healthcare & Drugs
SCORE
2
READ: Score Cards Explained
SAFETY/RISK SCORE
HIGH SAFETY
DETAILS: Safety/Risk Model for SSRX
Current Price:  n/a
F10k Day (2007-02-07): -100.00%$14.85
2009 Close: -100.00%$13.69
2010 Close: -100.00%$15.18
2011 Close: -100.00%$10.22
High (2012-10-16): -100.00%$14.25
Low (2012-07-31): -100.00%$10.15
Exchange:
Market Capitalization: n/a
Total Shares: 22.42 mill
Float: n/a
Avg Volume: 71.70 k
Short Interest: 127.20 k
Short Ratio: 0.97%1.8 d
Last Quarter: 2011-03-31
Revenue (MRQ): 18.06 mill
Net Income (MRQ): 3.39 mill
all financial data provided without warranty